Previously Funded Research

than 30% of NSCLC patients carry mutations in the KRAS oncogene. Yet, there

are no effective KRAS inhibitors in the clinic. Dr. Xue and his team aim to

investigate inhibitors of the NF-kB pathway as a new targeted therapy for

KRAS-mutant lung cancer. First, they will identify mechanisms of drug

resistance to NF-κB inhibitors using genetic screens. Second, they will

determine the therapeutic efficacy of a combination of NF-κB and MEK

inhibitors in a mouse model of lung cancer. These studies will allow the team

to devise a new approach in exploring NF-κB as an Achilles’ heel in

KRAS-mutant lung cancer, and develop combinatorial treatment for these

patients.